| Identification | Back Directory | [Name]
BIIB129 | [CAS]
2770960-52-4 | [Synonyms]
BIIB129
N-Methyl-N-(cis-3-methyl-3-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)oxy)cyclobutyl)acrylamide
2-Propenamide, N-methyl-N-[cis-3-methyl-3-[[6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]oxy]cyclobutyl]- | [Molecular Formula]
C19H22N6O2 | [MOL File]
2770960-52-4.mol | [Molecular Weight]
366.42 |
| Hazard Information | Back Directory | [Uses]
BIIB129 is a covalent, selective, small molecule inhibitor of Bruton's tyrosine kinase (BTK) capable of penetrating the blood-brain barrier. BIIB129 inhibits the activity of BTK by covalently binding to Cys481 in BTK, thereby affecting the function of B cells and myeloid cells. BIIB129 can be used in multiple sclerosis (MS) research[1]. | [References]
[1] Himmelbauer M K, et al. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis[J]. Journal of Medicinal Chemistry, 2024. DOI:10.1021/acs.jmedchem.4c00220 |
|
|